VEGFA and Peritoneal Fibrosis: Except for bevacizumab, which has already been investigated for PD fibrosis, our analysis also identified the VEGF inhibitors ranibizumab, aflibercept, brolucizumab, and abicipar pegol as potential investigational molecules to address peritoneal fibrosis.